Celltrion secures $730 mn to buy biosimilar unit shares, pursue M&A
Celltrion Holdings Co. has secured 1 trillion won ($732 million) in fresh funding and plans to spend half of it this year to buy shares in its biosi...
Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma
BOSTON – Lotte Biologics Co. has signed a deal to manufacture an antibody therapy for British biotech startup Ottimo Pharma as the South Korea...
Celltrion shares rise after bonus issue announcement
Celltrion Inc., South Korea’s largest biosimilar developer, will issue bonus shares to bolster its stock performance, which has been in the do...
Samsung Biologics to spin off biosimilar unit Samsung Bioepis
Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...
S.Korea’s Lunit installs breast cancer AI diagnostic tool at 200 US hospitals
Lunit Inc., a South Korean AI-powered cancer diagnostics company, said on Monday that more than 200 healthcare institutions across the US have now a...
Korea’s pharmaceutical exports set to top $10 bn, led by ‘K-M7’ champions
South Korea’s pharmaceutical exports are on course to surpass $10 billion this year, underscoring the country’s growing clout in the glo...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
POSCO to sell entire stake in Nippon Steel, ending equity ties
POSCO Holdings Inc. has decided to sell its entire stake in Nippon Steel Corp., according to industry sources on Wednesday, marking the end of their...
SillaJen: First to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
Samsung, Celltrion lead biosimilar market in Europe, US
Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...
Dongkuk to file anti-dumping petition vs Chinese color steel imports
Dongkuk Coated Metal Co. and SeAh Steel Corp. are set to file an anti-dumping complaint against Chinese rivals in March as the country plans to impo...
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Korean court rules in favor of Samsung Bioepis over Regeneron’s Eylea
A South Korean court on Friday ruled in favor of Samsung Bioepis Co. in a patent dispute against Regeneron Pharmaceuticals Inc., a US pharmaceutical...
South Korea to levy 38% anti-dumping duties on Chinese steel products
South Korea plans to impose up to 38% provisional anti-dumping duties on Chinese hot-rolled steel plates starting next month, judging that those pro...
Korea to probe Chinese, Japanese steel imports over anti-dumping claims
South Korea is set to launch an anti-dumping investigation into hot-rolled steel imports from China and Japan, according to government and industry ...
Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe
South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...
South Korea’s steel imports from China at 7-year high
South Korea’s imports of steel products from China climbed to their highest level in seven years despite a decrease in its total steel imports...
Korean drugmakers control more than half of European biosimilar market
South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...
Yuhan’s lung cancer drug gets OK in Europe
Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...
Celltrion obtains approval of Steqeyma from FDA
South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...
Celltrion’s 4 new biosimilars win EU approval recommendation
Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) rec...
Korean paper makers to file anti-dumping complaint vs Japanese rivals
South Korean corrugated cardboard sheet makers such as Asia Paper Manufacturing Co. have decided to file an anti-dumping complaint against Japanese ...
Celltrion gets approval of Omlyclo in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...
President of Latvia visits S.Korea's Daan Cancer Lab
Daan Cancer Laboratory under Severance Hospital said on Thursday it signed a memorandum of understanding (MOU) with the Latvian government to streng...
Celltrion to break ground on CDMO plant in 2025: Chairman Seo
South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...
Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug
Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...
Hanmi Pharma to move up launch of anti-obesity drug
South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...
